The monoamine transporter 2 inhibitor improved chorea symptoms as early as week 2.
A recent study presented at the International Congress of Parkinson’s Disease and Movement Disorders® has shed light on the potential of valbenazine, a vesicular monoamine transporter 2 inhibitor, in the treatment of chorea associated with Huntington disease (HD). The study reveals that valbenazine not only improves chorea symptoms but also does so as early as week 2, showcasing a fast onset of action.
- The study was led by Raja Mehanna, MD, from the University of Texas Health Science Center.
- The research involved an indirect comparison of data from clinical trials in adults with HD.
- Both valbenazine and deutetrabenazine, another vesicular monoamine transporter 2 inhibitor, were found to have a therapeutic effect during the maintenance phase.
- Deutetrabenazine is currently approved by the US Food and Drug Administration (FDA) for the treatment of chorea associated with HD, while valbenazine is under FDA review for this indication.
- The phase 3 trials of valbenazine (KINECT-HD) and deutetrabenazine (First-HD) showed significant improvements in chorea with active treatment versus placebo.
According to the Huntington’s Disease Society of America, approximately 30,000 Americans have HD.
More on Movement Disorders